Online inquiry

IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4202MR)

This product GTTS-WQ4202MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL2RA gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000417.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3559
UniProt ID P01589
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4202MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15967MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ9767MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA JS001
GTTS-WQ3664MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ6541MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA D2E7
GTTS-WQ7156MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FG-3019
GTTS-WQ2284MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ALXN1007
GTTS-WQ9359MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ11988MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MM-121
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW